Trial Profile

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Gynecological Malignant Tumors Failed or Intolerance to Standard First-Line Therapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HLX 43 (Primary)
Indications Adenosquamous carcinoma; Cervical cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
Focus Proof of concept; Therapeutic Use
Sponsors Shanghai Henlius Biotech

05 Dec 2025 Planned number of patients changed from 60 to 130.
05 Dec 2025 Results of phase 2 proof of concept (POC) study of Henlius PD-L1 antibody-drug conjugate (ADC) HLX43 in recurrent/metastatic cervical cancer were first presented in Proffered Paper Session at the 2025 ESMO Asia Congress, according to Shanghai Henlius Biotech Media Release.
05 Dec 2025 Results presented in the Shanghai Henlius Biotech Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com